Atezolizumab and Bevacizumab with Transarterial Chemoembolization in Hepatocellular Carcinoma: The DEMAND Trial Protocol
Najib Ben Khaled(LMU Klinikum), Enrico N. De Toni(LMU Klinikum), Martin Fuchs(München Klinik Bogenhausen), Florian P. Reiter(Universitätsklinikum Würzburg), Julia Mayerle(LMU Klinikum), Ursula Ehmer(TUM Klinikum), Ilja Kubisch(Klinikum Chemnitz), Philipp A. Reuken(Jena University Hospital), Daniel Rössler, Jens Ricke(LMU Klinikum), Marino Venerito(John Radcliffe Hospital), Marie‐Luise Berres, Bettina Oehrle(LMU Klinikum), Alexander Dechêne(Paracelsus Medical University), Henning Wege(Universität Hamburg), Daniel Teupser(LMU Klinikum), Arne Kandulski(University Hospital Regensburg), Max Seidensticker(LMU Klinikum), Christian M. Lange(Goethe University Frankfurt), Tom Luedde(Düsseldorf University Hospital), Dirk Waldschmidt, Michael Bitzer(University Children's Hospital Tübingen)
Cited by 35
Related Papers
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k